This case study outlines how we helped well-established biopharmaceutical company with the request for the insights they needed to quantify the looming threat of biosimilars entry to their lead indications, and explore strategies that they could potentially adopt to defend their market position.
The company needed to validate key assumptions on the revenue forecast of the branded biologic in its lead indications and erosion forecasts — for both patient share and drug pricing in the following ten years.
Download the case study to find out how the client leveraged in-depth Biosimilars Insights together with indication-specific intelligence from Disease Landscape & Forecast to generate and synthesize the insights needed to address the key business questions and support their strategy.
